YU23599A - Stabilizovani antihistaminski sirup - Google Patents

Stabilizovani antihistaminski sirup

Info

Publication number
YU23599A
YU23599A YU23599A YU23599A YU23599A YU 23599 A YU23599 A YU 23599A YU 23599 A YU23599 A YU 23599A YU 23599 A YU23599 A YU 23599A YU 23599 A YU23599 A YU 23599A
Authority
YU
Yugoslavia
Prior art keywords
stabilized
antihistamine syrup
syrup
antihistamine
acid
Prior art date
Application number
YU23599A
Other languages
English (en)
Inventor
Farah J. Munayyer
Frank Guazzo
Elliot I. Stupak
Imtiaz A. Chaudry
Joel A. Sequeira
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22209512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU23599(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of YU23599A publication Critical patent/YU23599A/sh
Publication of RS49609B publication Critical patent/RS49609B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Jedan antihistaminski sirup stabilisan je protiv degradacije aktivnog sastojka dodavanjem oko 0,05 do oko 5 mg/mL jedne aminopolikarboksilne kiseline kao što je neka so etilendiamintetrasirćetne kiseline.[An antihistaminic syrup is stabilized against degradation of the active ingredient, by the addition of about 0.05 to 5 mg/mL of aminopolycarboxylic acid, such as some salt of ethylenedia-minetetraacetic acid.
YUP-235/99A 1998-06-01 1999-05-27 Stabilizovani antihistaminski sirup RS49609B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/088,128 US6132758A (en) 1998-06-01 1998-06-01 Stabilized antihistamine syrup

Publications (2)

Publication Number Publication Date
YU23599A true YU23599A (sh) 2001-07-10
RS49609B RS49609B (sr) 2007-06-04

Family

ID=22209512

Country Status (29)

Country Link
US (4) US6132758A (sh)
EP (1) EP1082117B1 (sh)
JP (2) JP4166948B2 (sh)
AR (1) AR019147A1 (sh)
AT (1) ATE257705T1 (sh)
AU (1) AU754469B2 (sh)
CA (1) CA2333528C (sh)
CO (1) CO5011119A1 (sh)
CR (1) CR6035A (sh)
DE (1) DE69914192T2 (sh)
DK (1) DK1082117T3 (sh)
EG (1) EG23908A (sh)
ES (1) ES2211192T3 (sh)
GC (1) GC0000330A (sh)
GT (2) GT199900072A (sh)
HN (1) HN1999000081A (sh)
JO (1) JO2099B1 (sh)
ME (1) ME01664B (sh)
MY (1) MY123325A (sh)
NL (1) NL1012191C2 (sh)
NO (1) NO329124B1 (sh)
NZ (1) NZ508037A (sh)
PA (1) PA8474201A1 (sh)
PE (1) PE20000565A1 (sh)
PT (1) PT1082117E (sh)
RS (1) RS49609B (sh)
SV (1) SV1999000068A (sh)
TW (1) TW589197B (sh)
WO (1) WO1999062516A1 (sh)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
US6211246B1 (en) * 1999-06-10 2001-04-03 Mcneil-Ppc, Inc. Rapidly absorbed liquid compositions
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
AU2277101A (en) * 1999-12-20 2001-07-03 Schering Corporation Stable extended release oral dosage composition
SK287105B6 (sk) * 1999-12-20 2009-12-07 Schering Corporation Dvojvrstvový orálny dávkový prostriedok s predĺženým uvoľňovaním
MXPA02006347A (es) * 1999-12-21 2002-12-13 Schering Aktiengesllschft Tratamiento decondiciones alergicas e inflamatorias.
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
WO2001078782A1 (en) * 2000-04-14 2001-10-25 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
US20030216423A1 (en) * 2000-05-24 2003-11-20 Sergio Ulloa Stable liquid and solid formulations
PE20020055A1 (es) * 2000-05-25 2002-02-12 Schering Corp Formulaciones estables liquidas y solidas que comprenden una antihistamina no sedante y un descongestionante nasal
US20020035107A1 (en) * 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
IN192160B (sh) * 2000-07-17 2004-02-28 Ranbaxy Lab
CA2417661A1 (en) * 2000-08-02 2002-02-07 Malope Company Limited Diagnosis and treatment of non-ulcer dyspepsia based on hypothalamic-pituitary-adrenal axis abnormality
US6720002B2 (en) 2001-07-20 2004-04-13 R.P. Scherer Technologies, Inc. Antihistamine formulations for soft capsule dosage forms
PE20030545A1 (es) * 2001-10-31 2003-06-19 Schering Corp Formulaciones de jarabe de ribavirina
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US20040101563A1 (en) * 2002-07-18 2004-05-27 Kundu Subhas C. Storage stable antihistaminic syrup formulations
US20100092562A1 (en) * 2002-11-26 2010-04-15 Hollenbeck R Gary Sustained-release drug delivery compositions and methods
US6635654B1 (en) 2003-01-09 2003-10-21 Allergan, Inc. Ophthalmic compositions containing loratadine
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
DE602004004453T2 (de) * 2003-03-12 2007-11-08 Teva Pharmaceutical Industries Ltd. Stabile pharmazeutische zusammensetzungen mit desloratadin
JP3881640B2 (ja) * 2003-08-08 2007-02-14 塩野義製薬株式会社 ロラタジンを含むドライシロップ剤
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
WO2005076829A2 (en) * 2004-02-05 2005-08-25 Taro Pharmaceuticals U.S.A., Inc. Stable loratadine spill resistant formulation
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
GB0417909D0 (en) * 2004-08-11 2004-09-15 Novartis Consumer Health Sa Drop preparations
US20060093631A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20070009558A1 (en) * 2004-12-22 2007-01-11 David Harris Sugar-free storage-stable antihistaminic syrups
EP1833461A1 (en) 2004-12-22 2007-09-19 Schering Corporation Pharmaceutical formulations
US20060205752A1 (en) * 2005-03-14 2006-09-14 Keith Whitehead Stabilized hydrocodone pharmaceutical compositions with ethylenediaminetetraacetic acid
US20060275516A1 (en) * 2005-06-02 2006-12-07 Ram A N S Compositions and methods for the treatment of allergic rhinitis
ES2398960T3 (es) * 2005-06-17 2013-03-22 Aft Pharmaceuticals Limited Composición farmacéutica novedosa y su uso en un método para el tratamiento de pacientes con cangestión mucosa de las vías respiratorias altas
DOP2006000274A (es) 2005-12-14 2007-10-15 Sanofi Aventis Us Llc Formulación de suspensión de fexofenadina
EP2023957A2 (en) * 2006-06-07 2009-02-18 Morton Grove Pharmaceuticals, Inc. Oral liquid loratadine formulations and methods
BRPI0713933A2 (pt) * 2006-06-29 2012-12-18 Schering Corp xaropes anti-histamìnicos estáveis a armazenamento sem açúcar
US20080014275A1 (en) * 2006-07-13 2008-01-17 Buehler Gail K Pharmaceutical suspensions and related methods
WO2008105920A1 (en) * 2007-02-28 2008-09-04 Collegium Pharmaceutical, Inc. Antihistamine combination
EP2002733B1 (en) * 2007-06-08 2016-11-02 The Procter and Gamble Company Natural honey-containing compositions and method of preparation
US20090082385A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched desloratidine
CA2690490C (en) 2010-01-19 2012-06-26 Accucaps Industries Limited Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
JP5752578B2 (ja) * 2011-12-09 2015-07-22 ジェイ−メド ファーマシューティカルズ，インコーポレーティッド 鼻炎治療のための単一投与抗ヒスタミン薬／鬱血除去薬製剤
BR102012030828A2 (pt) 2012-12-03 2014-09-16 Ems Sa Composição farmacêutica compreendendo desloratadina e prednisolona e seu uso
CN104784110A (zh) * 2015-03-13 2015-07-22 浙江凯润制药有限公司 一种地氯雷他定糖浆制剂及其制备方法
US10576041B2 (en) 2016-09-26 2020-03-03 The Procter & Gamble Company Extended relief dosage form
CN109498569A (zh) * 2018-12-21 2019-03-22 湖北康源药业有限公司 一种氯雷他定糖浆及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU570306B2 (en) * 1984-02-15 1988-03-10 Schering Corporation 8-chloro-6, 11-dihydro-11-(4-piperidylidene)-5h-benzo (5,6) cyclohepta (1,2-b) pyridine and its salts.
US4783465A (en) * 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
US4829064A (en) * 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4975426A (en) * 1987-06-08 1990-12-04 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
JPH08502288A (ja) * 1992-10-09 1996-03-12 ザ、プロクター、エンド、ギャンブル、カンパニー 感昌症状を治療するための医薬組成物及び用法
EP0620001A1 (en) * 1993-04-16 1994-10-19 McNEIL-PPC, INC. Aqueous pharmaceutical suspension and process for preparation thereof
US5458879A (en) 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
JPH09124484A (ja) 1995-10-27 1997-05-13 Schering Purau Kk 点眼剤
US5912007A (en) * 1996-02-29 1999-06-15 Warner-Lambert Company Delivery system for the localized administration of medicaments to the upper respiratory tract and methods for preparing and using same
PE11399A1 (es) * 1996-10-31 1999-02-09 Schering Corp Combinacion de loratadina y un descongestionante para el tratamiento del asma
US5759579A (en) * 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
US5939426A (en) * 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup

Also Published As

Publication number Publication date
JP2005015485A (ja) 2005-01-20
NO329124B1 (no) 2010-08-30
US20030152595A1 (en) 2003-08-14
ATE257705T1 (de) 2004-01-15
DK1082117T3 (da) 2004-05-03
TW589197B (en) 2004-06-01
HN1999000081A (es) 1999-08-23
GT199900072A (es) 2000-11-16
JP2002516860A (ja) 2002-06-11
EP1082117B1 (en) 2004-01-14
US6514520B2 (en) 2003-02-04
NL1012191C2 (nl) 2000-01-04
WO1999062516A1 (en) 1999-12-09
CA2333528C (en) 2002-07-02
PA8474201A1 (es) 2001-07-31
PT1082117E (pt) 2004-05-31
SV1999000068A (es) 2000-06-23
GC0000330A (en) 2007-03-31
AU754469B2 (en) 2002-11-14
US6939550B2 (en) 2005-09-06
DE69914192D1 (de) 2004-02-19
ES2211192T3 (es) 2004-07-01
US6132758A (en) 2000-10-17
JO2099B1 (en) 2000-05-21
ME01664B (me) 2007-06-04
US20050261280A1 (en) 2005-11-24
GT199900072AA (es) 2000-11-16
DE69914192T2 (de) 2004-10-21
NZ508037A (en) 2002-11-26
JP4166948B2 (ja) 2008-10-15
AR019147A1 (es) 2001-12-26
EG23908A (en) 2007-12-30
CR6035A (es) 2008-11-26
PE20000565A1 (es) 2000-07-05
RS49609B (sr) 2007-06-04
US20020132805A1 (en) 2002-09-19
NL1012191A1 (nl) 1999-12-03
CO5011119A1 (es) 2001-02-28
CA2333528A1 (en) 1999-12-09
EP1082117A1 (en) 2001-03-14
NO20006079L (no) 2000-11-30
AU4308599A (en) 1999-12-20
MY123325A (en) 2006-05-31
NO20006079D0 (no) 2000-11-30

Similar Documents

Publication Publication Date Title
YU23599A (sh) Stabilizovani antihistaminski sirup
WO1999063826A3 (de) Mittel zur bekämpfung von pflanzenschädlingen
WO2001072728A3 (en) Novel piperazine derivatives
EP0852117A4 (en) IMPROVEMENT OF LIPID METABOLISM
NO2011026I2 (no) Eribulin eller et farmasøytisk akseptabelt salt derav
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
CA2382098A1 (en) Sustained-release, oral pharmaceutical forms of administration
FI950309A (fi) Proliiniamidijohdannaisia
PT975235E (pt) Formulacoes nutricionais contendo oligossacaridos
ES8609251A1 (es) Un procedimiento para preparar un compuesto de n-aril-n- -(4-piperidinil)-alcoxialquilamida
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
FI942499A0 (fi) Indolijohdannainen, menetelmä sen valmistamiseksi ja sen lääkekäyttö
WO1992019211A3 (en) Imidazobenzoquinones and composition for preventing or treating hypertension or congestive heart failure containing the same
CA2326339A1 (en) Use of dexmedetomidine for icu sedation
CA2129542A1 (en) Pharmaceutical preparation based on rhamnolipid
CA2219359A1 (en) Hydantoin derivatives as intermediates for pharmaceutical active compounds
EP1008345A4 (en) ANTI-ALLERGIC AGENTS
EP1026162A4 (en) ANTI-RHUMATISMAL AGENT
EP1219296A4 (en) SEBUM PRODUCTION INHIBITORS
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
EP1149832A4 (en) BENZAMIDE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THEM
EP0503079A4 (en) Pyridazinone-substituted ethynylphenyl derivative and remedy for circulatory organ disease containing the same as active ingredient
AU4732096A (en) Remedy for pulmonary heart
BG103779A (en) Crystallohydrate sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylpyrrolidine-3-ilidenmethyl)-1h-i ndole-2-carboxylic acid